SAFETY AND PHARMACOKINETICS OF NOVEL PI3K. INHIBITOR ART-001 IN ORAL PEDIATRIC FORMULATION FOR THE TREATMENT OF VASCULAR MALFORMATIONS.

被引：0
|
作者：
Tanaka, A. [1 ,2 ]
Uemura, N. [2 ]
Kuniyeda, K. [1 ,2 ]
Ando, H. [1 ,2 ]
Higashi, T. [3 ]
Nagabukuro, H. [1 ,2 ]
机构：
[1] AR Tham Therapeut, Yokohama, Kanagawa, Japan
[2] Oita Univ, Yufu, Oita, Japan
[3] CTD, Chuo Ku, Tokyo, Japan
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2021年 / 109卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
PII-041
引用
收藏
页码：S40 / S40
页数：1
相关论文
共 19 条
  • [1] A randomized, placebo-controlled study to evaluate safety and pharmacokinetics of ART-001 with a novel oral pediatric formulation in healthy subjects
    Tanaka, Akira
    Uemura, Naoto
    Kuniyeda, Kanako
    Ando, Haruhi
    Higashi, Toshinori
    Nagabukuro, Hiroshi
    CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2023, 16 (10): : 1898 - 1910
  • [2] A phase 2 randomized, double-blind trial of ART-001, a selective PI3Kα inhibitor, for the treatment of slow-flow vascular malformations
    Ozeki, Michio
    Tanaka, Akira
    Kuniyeda, Kanako
    Nozaki, Taiki
    Fujino, Akihiro
    Nomura, Tadashi
    Uemura, Naoto
    Suenobu, Souichi
    Aramaki-Hattori, Noriko
    Hayashi, Ayato
    Kato, Aiko
    Kiyosue, Hiro
    Imagawa, Kotaro
    Nagao, Munetomo
    Shimizu, Fumiaki
    Ochi, Junko
    Horiuchi, Saya
    Ohyama, Tetsuji
    Ando, Haruhi
    Nagabukuro, Hiroshi
    ORPHANET JOURNAL OF RARE DISEASES, 2025, 20 (01)
  • [3] Pharmacokinetics and Safety Of Idelalisib, a Novel PI3Kδ Inhibitor, In Japanese and Caucasian Subjects
    Jin, Feng
    Robeson, Michelle
    Zhou, Huafeng
    Moyer, Candra
    Ramanathan, Srini
    BLOOD, 2013, 122 (21)
  • [4] Pharmacokinetics and safety of idelalisib, a novel PI3Kδ inhibitor, in Japanese and Caucasian subjects
    Jin, Feng
    Robeson, Michelle
    Zhou, Huafeng
    Moyer, Candra
    Ramanathan, Srini
    CANCER RESEARCH, 2014, 74 (19)
  • [5] Safety, pharmacokinetics and dose-response characteristics of GSK2269557, an inhaled PI3Kδ inhibitor under development for the treatment of COPD
    Cahn, A.
    Hamblin, J. N.
    Begg, M.
    Wilson, R.
    Dunsire, L.
    Sriskantharajah, S.
    Montembault, M.
    Leemereise, C. N.
    Galinanes-Garcia, L.
    Watz, H.
    Kirsten, A. M.
    Fuhr, R.
    Hessel, E. M.
    PULMONARY PHARMACOLOGY & THERAPEUTICS, 2017, 46 : 69 - 77
  • [6] First-in-human study of PF-04691502, a small molecule oral dual inhibitor of PI3K and mTOR in patients with advanced cancer: Preliminary report on safety and pharmacokinetics
    Britten, C. D.
    Adjei, A. A.
    Millham, R.
    Houk, B.
    Wainberg, Z. A.
    Guthrie, T.
    Dy, G.
    LoRusso, P. M.
    EJC SUPPLEMENTS, 2010, 8 (07): : 121 - 122
  • [7] Mass balance, metabolism, and pharmacokinetics of [14C]amdizalisib, a clinical-stage novel oral selective PI3Kδ inhibitor for the treatment of non-hodgkin's lymphoma, in healthy Chinese volunteers
    Zhao, Chun-Yang
    Zhang, Li-Jun
    Sun, Chan
    Yu, Cheng-Yin
    Wang, Jian
    Sai, Yang
    Su, Wei-Guo
    Chen, Qian
    Wang, Wei
    Jia, Jing-Ying
    Liu, Gang-Yi
    Liu, Yan-Mei
    FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [8] A phase I dose-escalation study of the safety, pharmacokinetics and pharmacodynamics of XL147, a novel PI3K inhibitor administered orally to patients with advanced solid tumors
    Calvo, E.
    Edelman, G.
    Baselga, J.
    Kwak, E.
    Scheffold, C.
    Nguyen, L.
    Shapiro, G. I.
    EJC SUPPLEMENTS, 2008, 6 (12): : 69 - 69
  • [9] Characterisation of pharmacokinetics, safety and tolerability in a first-in-human study for AZD8154, a novel inhaled selective PI3Kγδ dual inhibitor targeting airway inflammatory disease
    Sadiq, Muhammad Waqas
    Asimus, Sara
    Belvisi, Maria G.
    Brailsford, Wayne
    Fransson, Rebecca
    Fuhr, Rainard
    Hagberg, Anette
    Hashemi, Mahdi
    Jensen, Tina Jellesmark
    Jonsson, Julia
    Keen, Christina
    Koernicke, Thomas
    Kristensson, Cecilia
    Maenpaa, Jukka
    Necander, Sofia
    Nemes, Szilard
    Betts, Joanne
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2022, 88 (01) : 260 - 270
  • [10] Mass balance, metabolic disposition, and pharmacokinetics of a novel selective inhibitor of PI3Kδ [14C] SHC014748M in healthy Chinese subjects following oral administration
    Guo, Fei
    Liu, Bingyan
    Li, Xiaoli
    Wang, Haidong
    Zhu, Xingyu
    Su, Yue
    He, Cuixia
    Zhu, Minhui
    Ding, Jiaxiang
    Xu, Yuanyuan
    Zhao, Xiangdi
    Wang, Ying
    Shan, Rongfang
    Zhu, Juan
    Xie, Jing
    Ge, Qin
    Fan, Ling
    Ding, Yuzhou
    Xie, Yunqiu
    Zhang, Chaoyang
    Li, Hongtao
    Wang, Hongju
    Zhou, Huan
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2023, 91 (02) : 143 - 156
12